Form 4: REGENXBIO CMO Boosts Stake with New Stock, Options

REGENXBIO's Chief Medical Officer, Steve Pakola, acquired 65,847 shares of common stock and 35,402 stock options on January 6, 2026.

Summary

• Steve Pakola, Chief Medical Officer of REGENXBIO Inc. (RGNX), acquired 65,847 shares of common stock through a time-based restricted stock unit (RSU) award.
• These RSU shares vest 25% annually on January 6, 2027, 2028, 2029, and 2030, contingent on continuous service to the Issuer.
• Pakola also acquired 35,402 stock options with an exercise price of $14.18 per share and an expiration date of January 6, 2036.
• The stock options vest 25% after 12 months of continuous service, with the remainder vesting in equal monthly installments over the 36 months following January 6, 2027.
• Following these transactions, Pakola beneficially owns 258,317 shares of common stock and 35,402 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The acquisition of a significant number of shares and options by a key executive (CMO) is generally a positive signal, indicating confidence in the company's future prospects and aligning management's interests with shareholders. The long-term vesting schedule reinforces this positive outlook.

Positives

• Chief Medical Officer Steve Pakola acquired a significant number of shares (65,847) and stock options (35,402), indicating management's confidence in the company's future.
• The awards are performance-based (time-based vesting), aligning management's interests with long-term shareholder value.

Future Outlook

The vesting schedules for both the RSUs and stock options extend several years into the future (up to 2030 for RSUs and 2036 for options), indicating a long-term commitment and incentive structure for the Chief Medical Officer.

Industry Context

This filing reflects standard executive compensation practices in the biotechnology industry, where long-term equity incentives like RSUs and stock options are used to attract, retain, and motivate key personnel, aligning their interests with the company's long-term success in a high-risk, high-reward sector like gene therapy.

Comparison to Industry Standards

• The use of time-based restricted stock units (RSUs) and stock options with multi-year vesting schedules is a common compensation strategy in the biotechnology and pharmaceutical sectors, similar to practices at companies like Sarepta Therapeutics or Alnylam Pharmaceuticals, to ensure executive retention and alignment with long-term value creation.
• The exercise price of $14.18 for the stock options likely reflects the market price on the grant date, a standard practice for incentive stock options.

Stakeholder Impact

• Shareholders: The acquisition of equity by a key executive can be viewed positively, signaling management's belief in the company's future and potentially increasing investor confidence.
• Employees: The compensation structure for a senior executive may influence overall compensation philosophy and morale.

Next Steps

• Continued service by Steve Pakola to ensure vesting of RSUs and stock options.
• Future vesting events for RSUs on January 6, 2027, 2028, 2029, and 2030.
• Future vesting events for stock options, with 25% vesting after 12 months of continuous service and the remainder monthly over 36 months following January 6, 2027.

Key Dates

Recommendation

While the insider acquisition of shares and options by the Chief Medical Officer is a positive signal of management confidence, a Form 4 filing alone typically does not provide enough comprehensive financial or strategic information to warrant a "buy" or "sell" recommendation. It reinforces a "hold" position for existing investors, suggesting continued monitoring of the company's performance and broader market conditions.

Keywords

REGENXBIO, RGNX, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, CMO, Executive Compensation, Biotechnology, Gene Therapy